Join Dr Ross Camidge and Dr Mark Socinski as they share insights into the selection of precision therapy for NSCLC based on tumor biomarkers and driver mutations, and strategies to proactively address treatment-related adverse events.
Are you confident using novel agents for acute myeloid leukemia (AML) in your practice? Listen to faculty experts discuss challenging patient cases and provide guidance on using new agents, creating individualized treatment plans, monitoring adverse events, and the role of measurable residual disease in AML management.